Post

New research · Hematology
Fish & shellfish immunology · 1d
Randomized trialFish & shellfish immunology · 2026

Hematology-centered characterization of β-glucan-mediated disease trajectory modulation during rock bream iridovirus (RBIV) infection.

Su-Mi Shin, Da-Seul Lee, Seok-Ju Lee … Myung-Hwa Jung
Read paper
HematologyRandomized trial

Beta-glucan treatment reduced rock bream iridovirus mortality to 60% in experimental infection.

Hematology-centered characterization of β-glucan-mediated disease trajectory modulation during rock bream iridovirus (RBIV) infection.

Su-Mi Shin et al. · Fish & shellfish immunology · 2026
Background

Rock bream iridovirus (RBIV) causes a rapid systemic infection, severe hematological disruption, and high mortality in rock bream (Oplegnathus fasciatus).

60%
Results
Cumulative mortality was 60% with beta-glucan, reduced from 100% in untreated fish.
More results

Although β-glucan is widely used as an immunostimulant in aquaculture, its influence on RBIV disease progression remains poorly understood.

Therefore, this study evaluated the effects of different β-glucan administration schedules on survival, viral dissemination, and blood-associated physiological responses during experimental RBIV infection.

More results

Compared with virus-only fish, β-glucan treatment improved survival while delaying systemic viral dissemination, reducing viral burden, and attenuating hematological deterioration throughout infection.

In contrast, biochemical responses showed comparatively limited treatment-associated effects.

“
Conclusion

These results further support the concept that preservation of hematological integrity represents a key component of disease resilience during RBIV infection.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
92.3%
Share of treated patients whose lymphoma shrank or cleared after treatment
Cohort Study
HR 2.59
sudden kidney damage meant over twice the risk of death for CAR-T recipients
Study
30%
About 30% of peptides from multiple myeloma cell lines stimulated CD8+ T-cell responses.
AI / Informatics
C-index = 96.0%
The model accurately predicted when initial leukemia treatment would not work
Cohort Study
97.30%
The AI model correctly identified aplastic anemia or myelodysplastic syndromes 97.30% of the time.
Cohort Study
55.9% vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
Cohort Study
OR 3.8
Each additional low lab value associated with 3.8 times higher odds of Multisystem Inflammatory Syndrome in Children.
Cohort Study
30% higher risk
increased risk of new low blood cell counts per 0.1 g/L C3 decrease